Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-04-16
2008-12-02
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S022000
Reexamination Certificate
active
07459461
ABSTRACT:
The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
REFERENCES:
patent: 4704382 (1987-11-01), Fowler et al.
patent: 4822780 (1989-04-01), Tsuda et al.
patent: 5508273 (1996-04-01), Beers et al.
patent: 6080738 (2000-06-01), Akahoshi et al.
patent: 6528514 (2003-03-01), Kobayashi et al.
patent: 633914 (1963-12-01), None
patent: WO 97/03679 (1997-02-01), None
patent: WO 03/035654 (2003-05-01), None
Sands et. al., “LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury”, Expert Opinion on Investigational Drugs, pp. 1907-1916, 1999.
CA 137:103177, “Elastase Inhibitors”, Journal de la Societe de Biologie (2001), 195 (2), 143-150.
Ca 126:234793, “Structure and function of thrombin receptor”, Ishii et. al., Nippon Domyaku Koka Gakkai, 1997.
Pharmaceutical salts, Berge S. et al 1977.
Schoofs et. al., “Trypsin and Chymotrypsin Inhibitors in Insects and Gut Leeches”, Current Pharmaceutical Design, 8, 483-491 8, 2002.
Chambers et. al., “Leukotriene antagonists: patents highlights 1996-1998”, Expert Opinion on Therapeutic Patents, 1999, 9 (1 19-26.
Numerof, et. al., “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis—Tryptase Inhibitors: a novel class of anti-inflammatory drugs”, Expert Opinion on Investigational Drugs (1997), 6 (7), pp. 811-817.
Ahn, et. al., “Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restonosis and Inflammatory Diseases”, Current Pharmaceutical Design, 2003, 9, 2349-2365.
PCT International Preliminary ExaminationReport for Appln. No. PCT/US02/33206 dated Aug. 8, 2003.
Yao, Yu-Lin, “Association between the Expression of Mast Cell Chymase and Intraperitoneal Adhesion Formation in Mice,” Journal of Surgical Research 92, 4-44 (2000).
Sands, Howard et al., “LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury,” Exp. Opin. Invest. Drugs (1999) 8(11);1907-1916.
Akahoshi, Fumihiko et al., “Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiles of Nonpeptidic Difluoromethylene Ketones as Novel Inhibitors of Human Chymase,” J. Med. Chem. 2001, 44, 1297-1304.
de Garavilla, et al., “A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase,” The Journal of Biological Chemistry, 280(18): 18001-18007 (2005).
Willem I. de Boer, “Perspectives for cytokine antagonist therapy in COPD,” Drug Discovery Today, 10(2): 93-106 (2005).
Peter J. Barnes, “New Treatments for COPD,” Nature Reviews, 1: 437-446 (2002).
Henning, et al., “Synthesis and Neuroleptic Activity of a Series of 1-[1-(Benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone Derivatives,” Journal of Medicinal Chemistry, 30: 814-819 (1987).
PCT International Search Report, PCT/US 02/33206 Oct. 17, 2002.
Bioorganic&Med. Chem. Lett., 1995, 5, (16), 1801-1806.
Ref. International J. Pharm.1986, 33, 201-217.
J. Pharm. Sci., Jan. 1977, 66(1), p. 1-19.
Greco, Michael N. et al., “Nonpeptide Inhibitors of Cathepsin G: Optimization of a Novel.beta—Ketophosphonic Acid Lead by Structure-Bassed Drug Design”, Journal of the American Chemical Society, 2002 124(15), pp. 3810-3811.
De Lombaert S., et al, Non-Peptidic Inhibitors of Neutral Endopeptidase 24.11, Design and Pharmacology of Orally Active Phosphonate Prodrugs,Bioorganic and Medicinal Chemistry Letters, 1995 5(2), 151-154.
De Lombaert S., et al,N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generatrion Neutral Endopeptidase (NEP, EC 3.424.11) Inhibitors,J. Med. Chem., 1994, 37, 498-511.
Katritsky, et. al.,Org. Prep. Proced. Int., 1990, 22(2), 209-213.
Deprele, et al.,J. Am. Chem. Soc., 2002, 124, 9386-9387.
Steininger,Chem. Ber., 1963, 96, 3184-3194 (w/English-language translation of Abstract).
Abraham, W.M., Pharmacology of allergen-induced early and late airway responses and antigen-induced airway hyperresponsiveness in allergic sheep,Pulmonary Pharmacology, 1989, 2, 33-40.
Almond Harold R.
Cesco-Cancian Sergio
de Garavilla Lawrence
Greco Michael N.
Hawkins Michael J.
Desai Rita J
Ortho-McNeil Pharmaceutical , Inc.
Stercho Yuriy P.
LandOfFree
Phosphonic acid compounds as inhibitors of serine proteases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphonic acid compounds as inhibitors of serine proteases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphonic acid compounds as inhibitors of serine proteases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031249